Armen Shanafelt - 08 Jun 2022 Form 4 Insider Report for Surface Oncology, Inc.

Reporting relationship: Director, 10%+ Owner
Issuer ticker: N/A
Reported as of: 08 Jun 2022
Net transaction value: $0
SEC form: 4
Accepted by SEC: 10 Jun 2022, 20:00:46 UTC
Prior SEC filing: 09 Jun 2022
Source filing: View source filing
Reporting owner signature: /s/ Jessica Fees, as Attorney-in-Fact

Key filing fact

Armen Shanafelt filed Form 4 for Surface Oncology, Inc. on 10 Jun 2022.

Key facts

This page summarizes Armen Shanafelt's Form 4 filing for Surface Oncology, Inc..
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 10 Jun 2022, 20:00.

Change

Previous filing in this sequence was filed on 09 Jun 2022.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

SURF transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value: $0
Shares: +24,000
Change %
Price: $0.000000
Shares after: 24,000
Date: 08 Jun 2022
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 24,000
Exercise price: $2.01
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

The Options shall vest in twelve equal monthly installments following the date of grant or, if earlier, upon the date of the next Annual Meeting; provided, however, that all vesting shall cease if the director resigns from the Board of Directors or otherwise ceases to serve as a director, unless the Board of Directors determines that the circumstances warrant continuation of vesting.